OptiNose sets terms for $100m IPO

OptiNose set terms for its IPO this week, according to a regulatory filing submitted to the SEC.
The company plans to offer 6.3 million shares at $15 – $17 apiece and funds affiliated with Avista Capital Partners intend to buy $25 million worth of shares as part of the offering, according to OptiNose. The company is slated to grant underwriters a 30-day option to buy up to an additional 937,500 shares of common stock at the IPO price.
Get the full story at our sister site, Drug Delivery Business News.
The post OptiNose sets terms for $100m IPO appeared first on MassDevice.

Source: Mass Device - October 5, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Funding Roundup Initial Public Offering (IPO) Otolaryngology Ear, Nose & Throat Pharmaceuticals Wall Street Beat OptiNose Source Type: news